<code id='88C144F64B'></code><style id='88C144F64B'></style>
    • <acronym id='88C144F64B'></acronym>
      <center id='88C144F64B'><center id='88C144F64B'><tfoot id='88C144F64B'></tfoot></center><abbr id='88C144F64B'><dir id='88C144F64B'><tfoot id='88C144F64B'></tfoot><noframes id='88C144F64B'>

    • <optgroup id='88C144F64B'><strike id='88C144F64B'><sup id='88C144F64B'></sup></strike><code id='88C144F64B'></code></optgroup>
        1. <b id='88C144F64B'><label id='88C144F64B'><select id='88C144F64B'><dt id='88C144F64B'><span id='88C144F64B'></span></dt></select></label></b><u id='88C144F64B'></u>
          <i id='88C144F64B'><strike id='88C144F64B'><tt id='88C144F64B'><pre id='88C144F64B'></pre></tt></strike></i>

          hotspot

          hotspot

          author:hotspot    Page View:56438
          Adobe

          By some measures, private equity investment lagged in 2023, a year marked by growing distress and high-profile downfalls among private equity-backed health care companies.

          Even so, three sectors still managed to see strong deal flow and prices: med spa, cardiology, and clinical trial sites, according to a new PitchBook report analyzing private equity investments in health care services in 2023. Each of the three niches continue to generate buzz among investors, even as other areas fizzle.

          advertisement

          It’s not that those three industries are perfect fits for private equity, it’s that the more obvious areas like autism therapists and physician practices are struggling with high interest rates and regulatory scrutiny, said Rebecca Springer, PitchBook’s lead health care analyst.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more
          Biogen joins immunology wave with $1.15 billion acquisition of HI
          Biogen joins immunology wave with $1.15 billion acquisition of HI

          RubyWallauforSTATBiogenisjoiningtheindustry’sfervoroverimmuneandinflammatorydiseasedrugdevelopmentwi

          read more
          How to save PrEP access — and even expand it
          How to save PrEP access — and even expand it

          UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

          read more

          Making the case for fair compensation in clinical trials

          AdobeI’vebeenonthreesidesofthehealthcareequation:I’vebeatenstage4colorectalcancer,I’mthemotherofason